Details zur Studie NOA-18

Kurzname

Studientitel

Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19p - IMPROVE CODEL: the NOA-18 trial. NOA-18/IMPROVE CODEL aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG), thereby delaying radiotherapy (RT) and adding the chemoradiotherapy (CHRT) concept at progression after initial radiation-free chemotherapy, allowing for an effective salvage treatment and delaying potentially deleterious side effects. QOS represents a new concept and is defined as OS without functional and/or cognitive and/or quality of life (QOL) deterioration regardless whether tumor progression or toxicity is the m

Diagnosegruppen

Linie

Phase

Fachbereich

Strahlentherapie

Studienregister